Clinical Trial Update: 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial update on 24-hour efficacy and ocular surface effects of Talfuprost in combination therapy for glaucoma and ocular surface disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Surface Disease

Drugs mentioned

• Talfuprost (Talfuprost)

Snippet

Sponsor: Aristotle University Of Thessaloniki | Conditions: Glaucoma, Ocular Surface Disease | Phase 4 | Status: COMPLETED